Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Raviteja Devalla

Vascular Surgery Dakota Dunes, SD Medical Doctor

NPI 1073975298 CMS profile 2974336

345 W Steamboat Dr Ste 601, Dakota Dunes, SD 57049

Open in the dashboard

General payments

$8,719

160 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Raviteja Devalla of Dakota Dunes, SD is reported in the CMS Open Payments database as having received $8,719 across 160 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 65th percentile of Vascular Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,248 25
2024 General $2,081 41
2023 General $2,164 30
2022 General $1,909 17
2021 General $577 16
2020 General $536 19
2019 General $203 12

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Raviteja Devalla
  • Vascular Surgery median
  • Middle half of Vascular Surgery
  • National median

In program year 2025, general payments to Raviteja Devalla were reported at $1,248. Among 3,991 Vascular Surgery profiles paid that year, the median was $924 and the middle half received between $273 and $2,636.

Show as a table
Year Raviteja Devalla Vascular Surgery median Middle half National median
2019 $203 $796 $226–$2,363 $163
2020 $536 $348 $118–$1,110 $114
2021 $577 $471 $158–$1,421 $132
2022 $1,909 $725 $222–$2,183 $149
2023 $2,164 $836 $257–$2,440 $160
2024 $2,081 $909 $252–$2,619 $164
2025 $1,248 $924 $273–$2,636 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. W. L. Gore & Associates, Inc. $2,557 32 payments
  2. Inari Medical, Inc. $1,673 23 payments
  3. Medtronic, Inc. $1,672 30 payments
  4. Stryker Corporation $401 4 payments
  5. Argon Medical Devices, Inc. $323 3 payments
  6. Boston Scientific Corporation $295 14 payments
  7. Acell, Inc. $252 5 payments
  8. Integra LifeSciences Corporation $207 5 payments
  9. AngioDynamics, Inc. $194 3 payments
  10. Silk Road Medical, Inc. $120 1 payment
  11. Other $1,025 40 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $7,733 156 payments
  2. Education $746 2 payments
  3. Travel and Lodging $240 2 payments
Products named General payments · program years 2019–2025
  1. CT THROMBECTOMY SYSTEM KIT $1,941 26 payments
  2. FLOWTRIEVER CATHETER, S $1,941 26 payments
  3. EXCLUDER Conformable AAA Endoprosthesis with Active Control $1,368 13 payments
  4. TurboHawk $570 4 payments
  5. GORE EXCLUDER AAA Endoprosthesis $470 4 payments
  6. HawkOne $332 7 payments
  7. GORE-TEX Vascular Graft $312 1 payment
  8. ENDURANT IIS $226 7 payments
  9. AURYON LASER SYSTEM 100-120 VAC $194 3 payments
  10. CLEANER $191 1 payment
  11. Other $3,327 102 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 5 drugs

Part D claims

344

Median for Vascular Surgery: 122

Drug cost

$76,730

Median for Vascular Surgery: $14,135

Branded share of claims

91%

Median for Vascular Surgery: 71%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Xarelto Rivaroxaban Brand 96 $40,688
Eliquis Apixaban Brand 43 $34,673
Clopidogrel Clopidogrel Bisulfate Brand 91 $684
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 83 $479
Atorvastatin Calcium Generic 31 $206

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,087 Part D prescribers listed as Vascular Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 131 billing codes

Paid by Medicare

$879,951

Medicare's payments for the services billed

Medicare patients

375

Average age 74

Services billed

2,745

164 women, 211 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Chronic kidney disease 49%
Arthritis 46%
Diabetes 44%
Ischemic heart disease 44%
Heart failure 38%
Atrial fibrillation 33%
COPD 32%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

160 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record